CPT code 38213 denotes the preparation of hematopoietic progenitor cell (HPC) solutions specifically to reduce residual platelets and prevent clumping. This preparatory step is a component of cellular therapy workflows that supports safe collection, storage, and transplantation of HPC products. Nationally, accurate coding for HPC processing affects facility billing, quality monitoring, and clinical documentation for stem cell and transplant programs.

Key payers in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the clinical context of HPC product handling, typical sites of service, and what to expect in payer coverage and billing practice reviews. The publication outlines common billing modifiers and operational considerations where available; when payer-specific policies are present, they are summarized to clarify prior authorization, bundling, and coverage distinctions.

This material is intended to help coding professionals, billing managers, and clinical administrators understand the role of CPT code 38213 within hematopoietic progenitor cell processing workflows and to locate the sections of the report that cover benchmarks, policy updates, and clinical context.